Praxis pauses one of its seizure programs after phase 2 fail
Fuente:
FierceBiotech
Praxis Precision Medicines’ epilepsy pipeline has suffered a setback after a next-gen NaV blocker failed to sufficiently reduce seizures in a phase 2/3 study.